Giant cell arteritis patients may be able to reduce treatment, study suggests

NCT ID NCT07108387

First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 21 times

Summary

This study looks at whether people with giant cell arteritis (GCA) who are in remission can safely stop or lower their dose of tocilizumab (Actemra). About 78 participants who have been on high-dose treatment for at least a year and off steroids for three months will either stop the drug completely or take a lower dose. The goal is to see how many stay in remission without the disease coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University School of Medicine: Division of Rheumatology

    RECRUITING

    Atlanta, Georgia, 30307, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital for Special Surgery, New York: Division of Rheumatology

    NOT_YET_RECRUITING

    New York, New York, 10021, United States

  • Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology

    RECRUITING

    Great Neck, New York, 11021, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwestern University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

  • University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology

    RECRUITING

    Pittsburgh, Pennsylvania, 15217, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.